[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465902":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":18,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Fundacion Clinic per a la Recerca Biomédica","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"miRFec test","The miRFec test corresponds to the combination of fecal hemoglobin concentration and fecal miRNA expression",[12],"Diagnostic Test: miRFec test",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DIAGNOSTIC_TEST","The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Antoni Castells, MD, PhD","Hospital Clinic of Barcelona","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Mireia Diaz","CONTACT","932275703","mdiazc@clinic.cat",[31],{"facility":22,"status":32,"city":33,"state":18,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Barcelona","08036","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],2.15899,41.38879,{"lat":41,"lon":40},[44],{"name":26,"role":27,"phone":45,"phoneExt":18,"email":29},"+34932275703",{"type":23,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Antoni Castells","Principal investigator","100465902","validation-of-a-microrna-based-fecal-mirfec-test-for-colorectal-cancer-screening-surveillance-and-diagnosis-100465902",false,"NCT05346757","Validation of a microRNA-based Fecal (miRFec) Test for Colorectal Cancer Screening, Surveillance and Diagnosis","Prospective, Multicenter, Comparative, Paired Study to Validate a microRNA-based Fecal Test for Colorectal Cancer Screening. The miRFec Study","miRFec","Inclusion Criteria:\n\n* Male or female aged 50 to 75 (average-risk) referred to colonoscopy-based CRC screening.\n* Male or female aged 30 to 80 with family history of CRC (moderate-risk) referred to colonoscopy-based CRC screening.\n* Male and female aged 18 or older with personal history of colorectal polyps referred to colonoscopy surveillance.\n* Male and female aged 18 or older with personal history of CRC referred to colonoscopy surveillance.\n* Male and female aged 18 or older with colorectal symptoms referred to diagnostic colonoscopy.\n\nExclusion Criteria:\n\n* Lack of informed consent to participate\n* Personal history of Lynch syndrome\n* Personal history of adenomatous or hamartomatous polyposis\n* Personal history of serrated polyposis syndrome\n* Personal history of inflammatory bowel disease\n* Personal history of total colectomy for any reason\n* Family history of Lynch syndrome\n* Family history of adenomatous or hamartomatous polyposis\n* Family history of serrated polyposis syndrome","ALL","18 Years","80 Years",{"count":61,"type":62},5390,"ESTIMATED","INTERVENTIONAL",[65],"NA","The present study aims to compare effectiveness and cost-effectiveness of the miRFec test with respect to fecal immunochemical test (FIT) for the detection of advanced colorectal neoplasm among individuals participating in colorectal cancer (CRC) screening, surveillance and diagnosis.",[68],"Colorectal Cancer","2025-03-11",{"date":71,"type":72},"2025-03-13","ACTUAL",{"date":74,"type":72},"2022-03-23",{"date":76,"type":62},"2027-01-31",{"name":5,"class":6},1]